News articles about Rigel Pharmaceuticals (NASDAQ:RIGL) have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Rigel Pharmaceuticals earned a coverage optimism score of 0.06 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 47.45507098145 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

A number of equities research analysts have commented on the company. Zacks Investment Research downgraded Rigel Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of Rigel Pharmaceuticals in a research report on Wednesday, May 3rd. BMO Capital Markets reiterated an “outperform” rating and set a $5.00 price objective (up previously from $4.00) on shares of Rigel Pharmaceuticals in a research report on Monday, June 19th. BidaskClub cut Rigel Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. Finally, ValuEngine cut Rigel Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Three investment analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $6.05.

Shares of Rigel Pharmaceuticals (NASDAQ RIGL) traded down 0.45% during trading on Friday, hitting $2.20. The company’s stock had a trading volume of 412,352 shares. The company’s market capitalization is $273.66 million. Rigel Pharmaceuticals has a 1-year low of $1.94 and a 1-year high of $4.38. The firm’s 50 day moving average is $2.45 and its 200-day moving average is $2.64.

Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.15) by $0.01. Rigel Pharmaceuticals had a negative return on equity of 105.86% and a negative net margin of 354.14%. During the same period in the prior year, the company posted ($0.15) earnings per share. Analysts forecast that Rigel Pharmaceuticals will post ($0.60) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Rigel Pharmaceuticals (RIGL) Receiving Somewhat Positive Media Coverage, Study Finds” was posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.

Insider Buying and Selling by Quarter for Rigel Pharmaceuticals (NASDAQ:RIGL)

Receive News & Ratings for Rigel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.